Stay updated on Nivolumab for Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab for Recurrent Meningioma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect the opening of accrual to Cohort 2 of a clinical trial for recurrent meningioma, with a focus on the drug nivolumab. Additionally, the principal investigator's name has been clarified, and the revision number has been updated.SummaryDifference56%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and removed a date reference of March 25, 2025, while adding a new date of December 19, 2024.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous estimated update date of December 19, 2024, and revision version 2.14.2.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to Nivolumab for Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent Meningioma Clinical Trial page.